Financial Performance - Net income reached $52 million, remaining stable QoQ and increasing by 1% YoY[2] - The Return on Equity (ROE) was 154%, decreasing by 10 bps QoQ and 134 bps YoY[2] - Net Interest Margin (NIM) stood at 236%, down 8 bps QoQ and 11 bps YoY[2] - The efficiency ratio improved to 269%, decreasing by 225 bps QoQ and increasing by 174 bps YoY[2] Portfolio and Deposits - The commercial book grew to $107 billion, up 6% QoQ and 23% YoY[2] - Total deposits increased to $59 billion, reflecting an 8% increase QoQ and a 24% increase YoY[2] - Non-Performing Loans (NPLs) represented 01% of the portfolio, decreasing by 1 bps QoQ and increasing by 4 bps YoY[2] Liquidity and Funding - Liquid assets accounted for 15% of total assets[13] - The Liquidity Coverage Ratio (LCR) was reported at 265x[12] Capitalization - The Common Equity Tier 1 (CET1) ratio was 151%[26] - The dividend payout ratio was 45%[27] Fee Income - Net fees totaled $106 million, decreasing by 11% QoQ and increasing by 12% YoY[2,40]

First Quarter 2025 Results May 6, 2025 NYSE/LSE: KOS Strictly Private and Confidential 1 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this presentation that address activities, events or developments that Kosmos Energy Ltd. ("Kosmos" or the "Company") expects, believes or a ...

Q1 2025 Results Presentation May 6, 2025 Changes in such assumptions and factors could cause actual future results to differ materially from those expressed in the forward-looking statements. All forward-looking statements in this presentation are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, the company does not unde ...

Q1 2025 Earnings Call May 6, 2025 IQVIA Template (V2.1.0) 100% 50% 75% 25% 1 Legal This presentation should be viewed in conjunction with IQVIA's Q1 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our second-quarter a ...

Investor Presentation May 2025 > hims & hers SUPPLEMENTAL PRESENTATION INTRODUCTION Safe Harbor Statement potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements This presentation has been prepared by Hims & Hers Health, Inc. ("we," "us," "our," "Hims & Hers," or the "Company"). involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be m ...

Financial Performance & Outlook - The company affirmed its 2025 earnings guidance of $5.68 to $6.08 per share[9] - Q1 2025 earnings reached $68.1 million, with a diluted EPS of $1.62[10] compared to $74.3 million and $1.77 diluted EPS in Q1 2024[12] representing an 8% decrease in net income[12] - The company projects a 14.2% Return on Equity (ROE) for 2025[13] - The electric segment is expected to have 7% earnings growth in 2025[13] Electric Segment & Rate Base - A net revenue increase of $13.1 million (6.18% increase) was achieved in the North Dakota rate case, implemented in March 2025[10, 19] - The North Dakota rate case resulted in an increased ROE to 10.1% (from 9.77%) and an equity layer of 53.5% (from 52.5%)[19] - The company anticipates significant rate base growth with a Compound Annual Growth Rate (CAGR) of 9.0%[22] Manufacturing & Plastics Segments - Sales prices in the plastics segment decreased by 11% in Q1 2025, while sales volumes increased by 13%[41] - Material input costs for the plastics segment decreased by 89%[41] - The BTD Georgia facility expansion was completed in Q1 2025, with the potential to generate up to $35 million in incremental annual revenue[10, 47] Capital Investments & Financing - The company plans total capital expenditures of $278 million in 2025[63] - Long-term debt issuances for Otter Tail Power Company are projected at $100 million for 2025[65] - The company anticipates normalized plastics earnings of $45-$50 million in 2028[70]

Statements contained herein reflect our views about future periods, including our future plans and performance, constitute "forward- looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, ac ...

Q1 2025 Performance - Total revenue reached $1764 million, a 64% increase compared to Q1 2024[7, 29] - Same-restaurant sales (SRS) grew by 18% in Q1 2025[7] - Net income attributable to Portillo's Inc was $3313 million, compared to $4562 million in the same quarter last year[28] - Restaurant-Level Adjusted EBITDA was $36656 million with a margin of 208%[7, 32] Fiscal 2025 Financial Targets - The company plans to open 12 new units[9, 12] - Same-restaurant sales are projected to grow by 1% to 3%[12] - Revenue growth is targeted at 10% to 12%[12] - Adjusted EBITDA growth is expected to be 5% to 8%[12] Long-Term Growth Algorithm - The company aims for low single-digit growth in same-restaurant sales[16] - Annual unit growth is targeted at 12% to 15%[16] - Revenue growth is projected in the low teens[16] - Adjusted EBITDA growth is expected in the mid-teens[16]

VYJUVEK Commercial Performance and Expansion - VYJUVEK has generated over $429 million in revenue since its launch[15] - Q1 2025 net revenue reached $88.2 million, a 95% increase compared to Q1 2024[16, 18] - The gross margin for Q1 2025 was 94%, with a gross to net of 17%[18] - Over 540 reimbursement approvals have been secured as of April 2025, with 45% from commercial payers and 39% from Medicaid[24, 25] - 97% of covered lives under commercial and Medicaid plans have positive access[25] Clinical Development Programs - Four clinical readouts are expected in 2025 for KB407 (cystic fibrosis), KB408 (AATD lung disease), KB304 (aesthetic skin conditions), and KB803 (ocular DEB)[19] - A Phase 1/2 study evaluating KB801 for neurotrophic keratitis is underway, with the first patient expected to be dosed this month[43] - Initial KB408 molecular data showed 35% AAT positive cells at baseline increasing to 39% after KB408 in patient 07[37] Financial Stability - The company's cash and investments totaled $7653 million as of March 31, 2025[54] - Non-GAAP R&D and SG&A expense guidance for the full year 2025 is $150 million to $175 million[55]

Where Intelligence Meets Infrastructure® Earnings Conference Call 2025 Second Quarter March 31, 2025 May 6, 2025 These slides are not intended to be a stand-alone presentation, but are for use in conjunction with the earnings call Non-GAAP Measures In an effort to provide investors with additional information regarding the Company's results as determined by accounting principles generally accepted in the United States ("GAAP"), the Company also provides non-GAAP information that management believes is usefu ...